J-mab Therapeutics ^None

J-mab Therapeutics is a Japanese company established in 2017 that focuses on developing anti-Hodgkin lymphoma drugs. The company specializes in creating antibodies that target cancer cells and has developed a new type of antibody that can penetrate cancer cells more effectively than traditional antibodies. These antibodies are called Anapocorisis antibodies and have pores that are over 100 times larger than conventional antibodies, allowing them to deliver drugs more efficiently.